• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Metabolic syndrome   pipeline review, h1 2014
 

Metabolic syndrome pipeline review, h1 2014

on

  • 52 views

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from ...

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Statistics

Views

Total Views
52
Views on SlideShare
52
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Metabolic syndrome   pipeline review, h1 2014 Metabolic syndrome pipeline review, h1 2014 Document Transcript

    • Metabolic Syndrome - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Metabolic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metabolic Syndrome and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Metabolic Syndrome The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Metabolic Syndrome and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Metabolic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Metabolic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Metabolic Syndrome Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Metabolic Syndrome pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 6 list Of Figures 7 introduction 8 global Markets Direct Report Coverage 8 metabolic Syndrome Overview 9 therapeutics Development 10 pipeline Products For Metabolic Syndrome Overview 10 pipeline Products For Metabolic Syndrome Comparative Analysis 11 metabolic Syndrome Therapeutics Under Development By Companies 12 metabolic Syndrome Therapeutics Under Investigation By Universities/institutes 15 metabolic Syndrome Pipeline Products Glance 17 late Stage Products 17 clinical Stage Products 18 early Stage Products 19 unknown Stage Products 20 metabolic Syndrome Products Under Development By Companies 21 metabolic Syndrome Products Under Investigation By Universities/institutes 22 metabolic Syndrome Companies Involved In Therapeutics Development 23 dainippon Sumitomo Pharma Co., Ltd. 23 ildong Pharmaceutical Co., Ltd. 24 chipscreen Biosciences Ltd 25 abeille Pharmaceuticals, Inc. 26 cortendo Invest Ab 27 spherix Incorporated 28 ache Laboratorios Farmaceuticos S/a 29 indus Biotech Private Limited 30 cardax Pharmaceuticals, Inc. 31 vivacell Biotechnology Espana S.l. 32 poxel Sa 33 shanghai Pharmaceuticals Holding Co Ltd 34 lead Discovery Center Gmbh 35 Metabolic Syndrome - Pipeline Review, H1 2014
    • mi.to. Technology S.r.l. 36 metabolic Syndrome Therapeutics Assessment 37 assessment By Monotherapy Products 37 assessment By Target 38 assessment By Mechanism Of Action 41 assessment By Route Of Administration 44 assessment By Molecule Type 46 drug Profiles 48 cs-038 - Drug Profile 48 product Description 48 mechanism Of Action 48 r&d Progress 48 ach-09 - Drug Profile 50 product Description 50 mechanism Of Action 50 r&d Progress 50 mbx-8025 - Drug Profile 51 product Description 51 mechanism Of Action 51 r&d Progress 51 chloroquine - Drug Profile 53 product Description 53 mechanism Of Action 53 r&d Progress 53 eplerenone - Drug Profile 54 product Description 54 mechanism Of Action 54 r&d Progress 54 spx-10624258 - Drug Profile 55 product Description 55 mechanism Of Action 55 r&d Progress 55 mb-12066 - Drug Profile 56 product Description 56 mechanism Of Action 56 r&d Progress 56 ab-3001 - Drug Profile 57 product Description 57 mechanism Of Action 57 r&d Progress 57 cdx-085 - Drug Profile 58 product Description 58 mechanism Of Action 58 r&d Progress 58 cde-001 - Drug Profile 60 product Description 60 mechanism Of Action 60 r&d Progress 60 gq-16 - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 next Generation Cortisol Inhibitor - Drug Profile 62 product Description 62 mechanism Of Action 62 r&d Progress 62 nd-630 - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 drug Targeting Ampd2 - Drug Profile 64 product Description 64 mechanism Of Action 64 r&d Progress 64 kh-064 - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 Metabolic Syndrome - Pipeline Review, H1 2014
    • metabolic Syndrome Program - Drug Profile 67 product Description 67 mechanism Of Action 67 r&d Progress 67 metabolic Syndrome Program - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 small Molecules To Inversely Agonize Beta3-adrenoreceptor For Cachexia, Metabolic Syndrome And Heart Failure - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 small Molecules For Inflammatory Diseases - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 myonectin - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 id-2244 - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 zln-024 - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 c-24 - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 drug Targeting Farnesoid X Receptor - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 apoptosis Inhibitor Of Macrophages - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 small Molecule For Cardiovascular And Metabolic Disorders - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 small Molecules To Inhibit Parp For Immunology, Oncology, Cardiovascular And Metabolic Disorders - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 drugs Targeting Acetyl-coa Carboxylase - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 11 Beta Hydroxysteroid Dehydrogenase 1 Inhibitors - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 drug Targeting Sirt - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 oligonucleotide To Inhibit Irak-3 For Cardiovascular And Metabolic Disorders - Drug Profile 82 product Description 82 mechanism Of Action 82 r&d Progress 82 tgr-5 Agonist Program - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 Metabolic Syndrome - Pipeline Review, H1 2014
    • indus-810 - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 metabolic Syndrome Recent Pipeline Updates 85 metabolic Syndrome Dormant Projects 87 metabolic Syndrome Discontinued Products 88 metabolic Syndrome Product Development Milestones 89 featured News & Press Releases 89 nov 11, 2013: Micardis Crosses 50 Million Patient-years Of Experience On 15th Anniversary 89 aug 28, 2012: Cardax Pharma To Obtain Chinese Patent Protection For Lead Compound Cdx-085 89 apr 26, 2012: Miragen Announces Publication Of Data On Mirg-9103 In Journal Cell 90 feb 27, 2012: Kadmon Announces Dosing Of First Patient In Phase I Study Of Kd025 91 sep 12, 2011: Cardiotrophin 1 Shows Promising Results For Treatment Of Obesity And Metabolic Syndrome 91 jun 07, 2008: Orexigen Therapeutics Announces That Contrave May Reverse The Incidence Of Metabolic Syndrome 92 appendix 94 methodology 94 coverage 94 secondary Research 94 primary Research 94 expert Panel Validation 94 contact Us 95 disclaimer 95 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Metabolic Syndrome - Pipeline Review, H1 2014